Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture

References

• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet1996348153515418950879
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA1998280207720829875874
   PubMed Web of Science ®Google Scholar
• WellsGACranneyAPetersonJAlendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database Syst Rev2008231CD00115518253985
   PubMed Web of Science ®Google Scholar
• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trialArthritis Rheum20014420221111212161
   PubMed Web of Science ®Google Scholar
• RingeJDDorstAFaberHAlendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm studyRheumatol Int20042411011313680141
   PubMed Web of Science ®Google Scholar
• FujiwaraSKasagiFMasunariNFracture prediction from bone mineral density in Japanese men and womenJ Bone Miner Res2003181547155312929946
   PubMed Web of Science ®Google Scholar
• KushidaKShirakiMNakamuraTThe efficacy of alendronate in reducing the risk of vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trialCurr Ther Res Clin Exp200263606620
   Web of Science ®Google Scholar
• KushidaKShirakiMNakamuraTAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up studyJ Bone Miner Metab20042246246815316867
   PubMed Web of Science ®Google Scholar
• ShirakiMKushidaKFukunagaMA double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosisOsteoporos Int19991018319210525709
   PubMed Web of Science ®Google Scholar
• UchidaSTaniguchiTShimizuTTherapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJ Bone Miner Metab20052338238816133688
   PubMed Web of Science ®Google Scholar
• KitazakiSMitsuyamaKMasudaJClinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitisAliment Pharmacol Ther20092942443019035979
   PubMed Web of Science ®Google Scholar
• OkadaYNawataMNakayamadaSAlendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapyJ Rheumatol2008352249225419031508
   PubMed Web of Science ®Google Scholar
• TakedaSKaneokaHSaitoTEffect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidolMod Rheumatol20081827127618427724
   PubMed Web of Science ®Google Scholar
• IwamotoJSatoYUzawaMComparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fracturesYonsei Med J20095047448119718394
   PubMed Web of Science ®Google Scholar
• OrimoHSugiokaYFukunagaMDiagnostic criteria of primary osteoporosisJ Bone Miner Metab199816139150
   Web of Science ®Google Scholar
• OrimoHHayashiYFukunagaMfor the Osteoporosis Diagnostic Criteria Review Committee, Japanese Society for Bone and Mineral ResearchDiagnostic criteria for primary osteoporosis: year 2000 revisionJ Bone Miner Metab20011933133711685647
   PubMed Web of Science ®Google Scholar
• IwamotoJMiyataASatoYFive-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fracturesTher Clin Risk Manag2009577377919851524
   PubMedGoogle Scholar
• IwamotoJSatoYUzawaMSeven years’ experience with alendronate in postmenopausal Japanese women with osteoporosisTher Clin Risk Manag2010620120620463781
   PubMed Web of Science ®Google Scholar
• IwamotoJSatoYUzawaMExperience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fracturesTher Clin Risk Manag2010659360021206758
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPSchachtESuperiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin d or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)Rheumatol Int20072742543417216477
   PubMed Web of Science ®Google Scholar
• FelsenbergDBockOBörstHAdditive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone massJ Musculoskelet Neuronal Interact201111344521364273
   PubMed Web of Science ®Google Scholar
• OrimoHShirakiMHayashiYEffects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosisCalcif Tissue Int1994543703768062152
   PubMed Web of Science ®Google Scholar
• IwamotoJTakedaTSatoYEarly changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with one-year response of lumbar bone mineral density to alendronate in Japanese postmenopausal women with osteoporosisJ Bone Miner Metab20052323824215838627
   PubMed Web of Science ®Google Scholar
• NishizawaYNakamuraTOhtaHfor the Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis SocietyGuidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)J Bone Miner Metab2005239710415750686
   PubMed Web of Science ®Google Scholar
• RuggieroSLDodsonTBAssaelLAfor the American Association of Oral and Maxillofacial SurgeonsAmerican Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 updateJ Oral Maxillofac Surg20096721219371809
   PubMed Web of Science ®Google Scholar
• LoJCO’RyanFSGordonNPfor the Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) InvestigatorsPrevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposureJ Oral Maxillofac Surg20106824325319772941
   PubMed Web of Science ®Google Scholar
• LenartBALorichDGLaneJMAtypical fractures of the femoral diaphysis in postmenopausal women taking alendronateN Engl J Med20083581304130618354114
   PubMed Web of Science ®Google Scholar
• RizzoliRAkessonKBouxseinMSubtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportOsteoporos Int20112237339021085935
   PubMed Web of Science ®Google Scholar
• GiustiAHamdyNAPapapoulosSEAtypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studiesBone20104716918020493982
   PubMed Web of Science ®Google Scholar
• GiustiAHamdyNADekkersOMAtypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and featuresBone201148596697121195812
   PubMed Web of Science ®Google Scholar
• ShaneEBurrDEbelingPRfor the American Society for Bone and Mineral ResearchAtypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2010252267229420842676
   PubMed Web of Science ®Google Scholar
• PazianasMCompstonJHuangCLAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res20102521020091928
   PubMed Web of Science ®Google Scholar
• HeckbertSRLiGCummingsSRUse of alendronate and risk of incident atrial fibrillation in womenArch Intern Med200816882683118443257
   PubMed Web of Science ®Google Scholar
• PazianasMCooperCEbetinoFHLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosisTher Clin Risk Manag2010632534320668715
   PubMed Web of Science ®Google Scholar
• VestergaardPSchwartzKPinholtEMRisk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort studyCalcif Tissue Int20108633534220309678
   PubMed Web of Science ®Google Scholar
• IwamotoJTakedaTSatoYComparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosisClin Rheumatol20072616116716565894
   PubMed Web of Science ®Google Scholar
• IwamotoJSatoYUzawaMThree-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetesDiabetes Res Clin Practice Epub 2011 Apr 25.
   Web of Science ®Google Scholar
• EnsrudKEBlackDMPalermoLTreatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention TrialArch Intern Med1997157261726249531231
   PubMed Web of Science ®Google Scholar
• ShirakiMYamazakiYShirakiYHigh level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatmentJ Bone Miner Metab20102857858420221651
   PubMed Web of Science ®Google Scholar
• MiyauchiAMatsumotoTSugimotoTEffects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phasesBone20104749350220580870
   PubMed Web of Science ®Google Scholar
• RingeJDSchachtEDukasLPotency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosisArzneimittelforschung20116110411121428245
   PubMed Web of Science ®Google Scholar
• SchachtERingeJDRisk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective studyArzneimittelforschung201161405421355445
   PubMed Web of Science ®Google Scholar
• BischoffHABorchersMGuadtFIn situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissueHistochem J200133192411352397
   PubMedGoogle Scholar
• Bischoff-FerrariHADawson-HughesBWillettWCEffect of vitamin D on falls: a meta-analysisJAMA20042911999200615113819
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHAWillettWCWongJBFracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trialsJAMA20052932257226415886381
   PubMed Web of Science ®Google Scholar